Technology Assessment for New Oncology Drugs
- 1 January 2013
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 19 (1), 6-11
- https://doi.org/10.1158/1078-0432.ccr-12-1819
Abstract
Health technology assessment (HTA) has become the key health policy instrument for managing the introduction and use of new oncology drugs in Europe. While the methodology of technology assessment, including calculations of cost-effectiveness, is applicable in principle also to oncology, the implementation in practice has its specific problems and consequences. Most of them are linked to the specific need to do the assessment early in the development, with limited data on outcome in clinical practice. Technology assessments ask for estimates of gains in mean survival, whereas trials are powered to study differences in progression-free or overall median survival. The development of targeted therapies and personalized cancer medicine offers opportunities but also increases the complexity of the assessment. Joint assessment of a diagnostic and a new treatment increases the number intervention strategies that must be considered, and thus the need for data. The translation from efficacy in trials to relative effectiveness in clinical practice must also be considered. The close link between pricing of new oncology drugs and their cost-effectiveness makes the use of technology assessment for policy decisions complicated for all stakeholders involved. But without an obvious alternative that is better, the likely future is that HTA will play an increasing role in informing policy decisions aimed at evidence-based cancer care. Clin Cancer Res; 19(1); 6–11. ©2013 AACR.Keywords
This publication has 16 references indexed in Scilit:
- The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer TherapiesHealth Outcomes Research in Medicine, 2012
- Using QALYs in CancerPharmacoEconomics, 2011
- Application of cost–effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemiaPharmacogenomics, 2011
- Relative effectiveness and the European pharmaceutical marketThe European Journal of Health Economics, 2011
- An Analysis of NICEʼs ‘Restricted’ (or ‘Optimized’) DecisionsPharmacoEconomics, 2010
- Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturersHealth Policy, 2010
- Ten arguments for a societal perspective in the economic evaluation of medical innovationsThe European Journal of Health Economics, 2009
- Key principles for the improved conduct of health technology assessments for resource allocation decisionsInternational Journal of Technology Assessment in Health Care, 2008
- PrefaceAnnals of Oncology, 2007
- Cost of Cancer Care: Issues and ImplicationsJournal of Clinical Oncology, 2007